Published in Cancer on June 15, 1998
Establishing an Inflammatory Breast Cancer Registry | NCT00340158
Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst (2005) 4.14
Early onset of breast cancer in a group of British black women. Br J Cancer (2008) 2.47
Epidemiology of inflammatory breast cancer (IBC). Breast Dis (2006) 2.46
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res (2009) 1.48
Update on inflammatory breast cancer. Breast Cancer Res (2005) 1.29
Analysis of RhoC expression and lymphovascular emboli in inflammatory vs non-inflammatory breast cancers in Egyptian patients. Breast (2009) 1.11
Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients. Breast Cancer Res Treat (2007) 1.11
Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion. Breast Cancer Res (2011) 1.07
Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties. Int J Biochem Cell Biol (2013) 0.99
An "elite hacker": breast tumors exploit the normal microenvironment program to instruct their progression and biological diversity. Cell Adh Migr (2012) 0.99
Human cytomegalovirus infection enhances NF-κB/p65 signaling in inflammatory breast cancer patients. PLoS One (2013) 0.98
Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008. Breast Cancer Res Treat (2012) 0.96
Association of inflammatory and noninflammatory breast cancer with socioeconomic characteristics in the Surveillance, Epidemiology, and End Results database, 2000-2007. Cancer Epidemiol Biomarkers Prev (2011) 0.96
Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer (2008) 0.94
What is inflammatory breast cancer? Revisiting the case definition. Cancers (Basel) (2010) 0.90
What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma? Breast Cancer Res Treat (2011) 0.89
Short- and long-term cause-specific survival of patients with inflammatory breast cancer. BMC Cancer (2005) 0.87
Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin. BMC Cancer (2008) 0.86
A comparison of cholesterol uptake and storage in inflammatory and noninflammatory breast cancer cells. Int J Breast Cancer (2012) 0.86
Breast metastases of gastric signet-ring cell carcinoma: a report of two cases and review of the literature. Onco Targets Ther (2014) 0.84
The current understanding of the molecular determinants of inflammatory breast cancer metastasis. Clin Exp Metastasis (2006) 0.84
Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up. Br J Cancer (2007) 0.84
Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome. Ann Oncol (2008) 0.83
Spontaneously-forming spheroids as an in vitro cancer cell model for anticancer drug screening. Oncotarget (2015) 0.81
Lapatinib: new opportunities for management of breast cancer. Breast Cancer (Dove Med Press) (2010) 0.81
Inflammatory breast cancer: New factors contribute to disease etiology: A review. J Adv Res (2013) 0.81
Inflammatory breast cancer in north Africa: comparison of clinical and molecular epidemiologic characteristics of patients from Egypt, Tunisia, and Morocco. Breast Dis (2013) 0.80
First description of feline inflammatory mammary carcinoma: clinicopathological and immunohistochemical characteristics of three cases. Breast Cancer Res (2004) 0.80
A comparison of criteria to identify inflammatory breast cancer cases from medical records and the Surveillance, Epidemiology and End Results data base, 2007-2009. Breast J (2013) 0.80
Importance of hereditary and selected environmental risk factors in the etiology of inflammatory breast cancer: a case-comparison study. BMC Cancer (2016) 0.76
Incidence of inflammatory breast cancer in women, 1992-2009, United States. Ann Surg Oncol (2013) 0.75
Photodynamic therapy as an effective therapeutic approach in MAME models of inflammatory breast cancer. Breast Cancer Res Treat (2015) 0.75
Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer. Cancer Epidemiol (2015) 0.75
Targeted treatment of advanced and metastaticbreast cancer with lapatinib. Onco Targets Ther (2008) 0.75
Inflammatory breast cancer: is it really a separate entity? Ecancermedicalscience (2012) 0.75
Beta protein 1 homeoprotein induces cell growth and estrogen-independent tumorigenesis by binding to the estrogen receptor in breast cancer. Oncotarget (2016) 0.75
Characterizing inflammatory breast cancer among Arab Americans in the California, Detroit and New Jersey Surveillance, Epidemiology and End Results (SEER) registries (1988-2008). Springerplus (2013) 0.75
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol (1999) 7.59
Non-invasive in vivo characterization of breast tumors using photon migration spectroscopy. Neoplasia (2000) 4.42
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol (1999) 3.62
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet (2000) 3.25
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis (2003) 2.85
Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol (1983) 2.64
Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet (1998) 2.50
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst (1991) 2.38
Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol (1997) 2.36
Carcinoma of the male breast. Ann Intern Med (1992) 2.27
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol (1996) 2.27
Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol (2000) 2.19
The dose-effect relationships between torture and psychiatric symptoms in Vietnamese ex-political detainees and a comparison group. J Nerv Ment Dis (1998) 2.12
Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys (1989) 2.09
Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol (1995) 2.08
Non-invasive measurements of breast tissue optical properties using frequency-domain photon migration. Philos Trans R Soc Lond B Biol Sci (1997) 2.05
Inflammatory breast cancer: a review. J Clin Oncol (1992) 1.93
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med (1980) 1.91
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol (1995) 1.85
Long-term cancer patient survival in the United States. Cancer Epidemiol Biomarkers Prev (1998) 1.83
Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res (1986) 1.82
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst (2000) 1.81
Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer (1988) 1.79
Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am (1998) 1.77
Rationale, design and methods for process evaluation in the HEALTHY study. Int J Obes (Lond) (2009) 1.70
Biologic plausibility in causal inference: current method and practice. Am J Epidemiol (1998) 1.67
Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med (1994) 1.66
The unipolar Shigella surface protein IcsA is targeted directly to the bacterial old pole: IcsP cleavage of IcsA occurs over the entire bacterial surface. Mol Microbiol (1999) 1.66
Early and delayed clinical cardiotoxicity of doxorubicin. Cancer (1985) 1.61
Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg (1999) 1.60
Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol (1997) 1.58
Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Ann Surg Oncol (1998) 1.58
Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer (2001) 1.57
Estrogen receptor: a prognostic factor in breast cancer. Cancer (1981) 1.51
Sequencing of chemotherapy and radiation in lymph node-negative breast cancer. Cancer J Sci Am (1999) 1.48
Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up. Ann Oncol (2000) 1.46
Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridization reveals a consistent pattern of chromosomal alterations. Genes Chromosomes Cancer (1999) 1.45
Racial differences in the distribution of anterior circulation occlusive disease. Neurology (1984) 1.43
Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res (1997) 1.43
Dr fimbriae operon of uropathogenic Escherichia coli mediate microtubule-dependent invasion to the HeLa epithelial cell line. J Infect Dis (1997) 1.43
The validity of posttraumatic stress disorder among Vietnamese refugees. J Trauma Stress (1997) 1.42
The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg (1989) 1.41
Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther (2000) 1.41
Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg (1998) 1.40
Overexpression of the retinoic acid-responsive gene Stra6 in human cancers and its synergistic induction by Wnt-1 and retinoic acid. Cancer Res (2001) 1.40
Congenital palatal ulcers in newborn infants with cleft lip and palate: diagnosis, frequency, and significance. Cleft Palate Craniofac J (1996) 1.38
Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Natl Cancer Inst (1997) 1.35
The validity of screening for post-traumatic stress disorder and major depression among Vietnamese former political prisoners. Acta Psychiatr Scand (1997) 1.34
Causes of death in breast cancer: a clinicopathologic study. Cancer (1980) 1.34
Clinical course of breast cancer patients with liver metastases. J Clin Oncol (1987) 1.32
Statistical Aspects of Coding and Tabulating Medical Data on Birth and Stillbirth Certificates. Am J Public Health Nations Health (1943) 1.29
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol (2001) 1.28
Multimodal treatment of locoregionally advanced breast cancer. Cancer (1983) 1.26
On the Influence of Density of Population Upon the Rate of Reproduction in Drosophila. Proc Natl Acad Sci U S A (1922) 1.24
Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis. Breast Cancer Res Treat (2000) 1.24
Repeated excimer laser treatment after photorefractive keratectomy. Arch Ophthalmol (1992) 1.23
Erythropoietin is both a mitogen and a survival factor. Blood (1991) 1.23
The absence of desmin leads to cardiomyocyte hypertrophy and cardiac dilation with compromised systolic function. J Mol Cell Cardiol (1999) 1.22
Reflectance measurements of layered media with diffuse photon-density waves: a potential tool for evaluating deep burns and subcutaneous lesions. Phys Med Biol (1999) 1.21
Inflammatory breast cancer and body mass index. J Clin Oncol (1998) 1.21
Diet-induced adiposity alters the serum profile of inflammation in C57BL/6N mice as measured by antibody array. Diabetes Obes Metab (2009) 1.19
Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer (1999) 1.19
The risk of breast cancer following spontaneous or induced abortion. Cancer Causes Control (1997) 1.18
Role of decay-accelerating factor domains and anchorage in internalization of Dr-fimbriated Escherichia coli. Infect Immun (2000) 1.17
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist (2001) 1.17
Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res (1993) 1.13
Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol (1999) 1.13
Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol (1997) 1.12
Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer. Ann Surg Oncol (2000) 1.12
Cancer statistics for African Americans, 1996. CA Cancer J Clin (1996) 1.11
Nicotine up-regulates expression of orexin and its receptors in rat brain. Endocrinology (2000) 1.10
Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol (1996) 1.10
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol (2000) 1.09
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol (2008) 1.07
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg (2001) 1.06
Leptin and prostate cancer. Prostate (2001) 1.06
Nicotine administration enhances NPY expression in the rat hypothalamus. Brain Res (2000) 1.05
The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. Am J Surg (2000) 1.05
Panic disorder among Vietnamese refugees attending a psychiatric clinic: prevalence and subtypes. Gen Hosp Psychiatry (2001) 1.05
Splenic marginal zone B-cell and thymic T-cell lymphomas in p53-deficient mice. Lab Invest (1999) 1.05
Prolonging microtubule dysruption enhances the immunogenicity of chronic lymphocytic leukaemia cells. Clin Exp Immunol (2009) 1.05
The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy. Cancer (2000) 1.05
Sensitivity of orexin-A binding to phospholipase C inhibitors, neuropeptide Y, and secretin. Biochem Biophys Res Commun (2000) 1.05
Decay-accelerating factor and cytoskeleton redistribution pattern in HeLa cells infected with recombinant Escherichia coli strains expressing Dr family of adhesins. Infect Immun (1999) 1.04
Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Mol Carcinog (2000) 1.04
Role of adjuvant chemotherapy in male breast cancer. Cancer (1989) 1.04
Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. Cancer Treat Rep (1979) 1.03
Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat (1982) 1.03
Pelvic inflammatory disease isolates of Neisseria gonorrhoeae are distinguished by C1q-dependent virulence for newborn rats and by the sac-4 region. Infect Immun (1997) 1.03
Calorie restriction reduces ulcerative dermatitis and infection-related mortality in p53-deficient and wild-type mice. J Invest Dermatol (1998) 1.02
Present status of anthracyclines in the adjuvant treatment of breast cancer. Drugs (1993) 1.02
Results of adjuvant chemotherapy trials in breast cancer at M. D. Anderson Hospital and Tumor Institute. NCI Monogr (1986) 1.01
Binge eating, mood, and quality of life in youth with type 2 diabetes: baseline data from the today study. Diabetes Care (2011) 1.01
Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer (1985) 1.01
Constitutional von Hippel-Lindau (VHL) gene deletions detected in VHL families by fluorescence in situ hybridization. Cancer Res (1999) 1.01
Noninvasive indexes of cardiac systolic and diastolic function in hyperthyroid and senescent mouse. Am J Physiol (1996) 1.01
Cataract extraction with multifocal intraocular lens implantation: clinical, functional, and quality-of-life outcomes. Multicenter clinical trial in Germany and Austria. J Cataract Refract Surg (2000) 1.01
Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer (1990) 1.01